Chemical Compound Review:
Veliflapon (2R)-2-cyclopentyl-2-[4- (quinolin-2...
Synonyms:
BAY-X-005, Bay-x-1005, Bay-X1005, Bayx-1005, CHEMBL88712, ...
- Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. Titos, E., Clària, J., Planagumà, A., López-Parra, M., González-Périz, A., Gaya, J., Miquel, R., Arroyo, V., Rodés, J. J. Leukoc. Biol. (2005)
- Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test. Burchardt, E.R., Müller-Peddinghaus, R. Prostaglandins Leukot. Essent. Fatty Acids (1997)
- Clinical activity of leukotriene inhibitors. Harris, R.R., Carter, G.W., Bell, R.L., Moore, J.L., Brooks, D.W. Int. J. Immunopharmacol. (1995)
- The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Nickerson-Nutter, C.L., Medvedeff, E.D. Arthritis Rheum. (1996)
- Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Hatzelmann, A., Fruchtmann, R., Mohrs, K.H., Raddatz, S., Müller-Peddinghaus, R. Biochem. Pharmacol. (1993)
- No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005. Groen, H., Moesker, H.L., Leeuwenkamp, O.R., Sollie, F.A., Jonkman, J.H. Journal of clinical pharmacology. (1996)
- Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. Titos, E., Clària, J., Planagumà, A., López-Parra, M., Villamor, N., Párrizas, M., Carrió, A., Miquel, R., Jiménez, W., Arroyo, V., Rivera, F., Rodés, J. FASEB J. (2003)
- Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. Cunningham, F.M., Andrews, M., Landoni, M.F., Lees, P. J. Vet. Pharmacol. Ther. (1997)
- Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Hatzelmann, A., Fruchtmann, R., Mohrs, K.H., Raddatz, S., Matzke, M., Pleiss, U., Keldenich, J., Müller-Peddinghaus, R. Agents Actions (1994)
- Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. He, W., Pelletier, J.P., Martel-Pelletier, J., Laufer, S., Di Battista, J.A. J. Rheumatol. (2002)
- MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005. Roger, P., Gascard, J.P., Bara, J., de Montpreville, V.T., Brink, C. Mediators of inflammation. (2001)
- Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005. Müller-Peddinghaus, R. J. Physiol. Pharmacol. (1997)